Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory/relapsed euroblastoma Version 8.0 dated
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Lorlatinib

Description: A document based on Lorlatinib, a lung cancer condition.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Lorlatinib.pdf

Blood culture sampling policy April 2022 v8

Description: Blood Culture Sampling Policy for Adult and Paediatric Patients Trust reference Description Version number 8.0 This policy lists indications for taking blood cultures and describes ho
Url: /Media/UHS-website-2019/Docs/Policies/Blood-culture-sampling-policy-April-2022-v8.pdf

Papers Trust Board - 9 September 2025

Description: Date Time Location Chair Apologies Agenda Trust Board – Open Session 09/09/2025 9:00 - 13:00 Conference Room, Heartbeat Education
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-9-September-2025.pdf

Appendix C - HBIG 200 IU neoanates risk assessment and prescription form

Description: Hepa atitis B Immun noglobulin (H HBIG) for pos st-exposure prophylaxis (PEP) in NEONA ATES born
Url: /Media/UHS-website-2019/Docs/Post-Exposure-Prophylaxis-Policy/AppendixC-HBIG200IUNeoanatesRiskAssessmentandPrescriptionForm.pdf

Annual-report-2018-19

Description: ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Ibrutinib (MCL) (560mg)

Description: Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Lymphoma with cycl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf

InP IVE-Epirubicin-Etoposide-Ifosfamide Ver1.1

Description: Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE (IVE) Inpatient Regimen Regimen • Lymphoma – InP-IVE-Epirubicin-Etoposide-Ifosfa
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-IVE-Epirubicin-Etoposide-Ifosfamide.pdf

InP RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Ver1.1

Description: Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVE) Inpatient Regimen Regimen Lymphoma – InP-RIVE-Ep
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab.pdf

Annual report 2021-2022

Description: 2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

1 to 10 of 13

Previous 1 2 Next